{"pmid":32337825,"title":"High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","text":["High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable.","Am J Transplant","Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern","32337825"],"abstract":["We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable."],"journal":"Am J Transplant","authors":["Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337825","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15949","topics":["Prevention"],"weight":1,"_version_":1665264685630357504,"score":8.574329,"similar":[{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["tocilizumab","remdesivir","Azithromycin","Hydroxychloroquine"],"_version_":1664636704083935233,"score":343.43945},{"pmid":32270388,"title":"Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","text":["Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data.","Hepatol Int","Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh","32270388"],"abstract":["The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data."],"journal":"Hepatol Int","authors":["Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270388","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10041-1","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["India"],"countries":["India"],"countries_codes":["IND|India"],"_version_":1664637315663790080,"score":322.4989},{"pmid":32302212,"title":"COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation.","text":["COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation.","We present a case of COVID-19 hepatitis in a living donor liver allograft recipient whose donor subsequently tested positive for COVID-19. The patient is a female infant with biliary atresia (failed Kasai procedure). She recovered well, with improving liver function tests for 4 days. On post-operative day (POD) 4 the patient developed respiratory distress and fever. COVID-19 testing (polymerase chain reaction) was positive. Liver function tests increased approximately 5-fold. Liver biopsy showed moderate acute hepatitis with prominent clusters of apoptotic hepatocytes and associated cellular debris. Lobular lymphohistiocytic inflammation was noted. Typical portal features of mild to moderate acute cellular rejection were also noted.","Arch Pathol Lab Med","Lagana, Stephen M","De Michele, Simona","Lee, Michael J","Emond, Jean C","Griesemer, Adam D","Tulin-Silver, Sheryl A","Verna, Elizabeth C","Martinez, Mercedes","Lefkowitch, Jay H","32302212"],"abstract":["We present a case of COVID-19 hepatitis in a living donor liver allograft recipient whose donor subsequently tested positive for COVID-19. The patient is a female infant with biliary atresia (failed Kasai procedure). She recovered well, with improving liver function tests for 4 days. On post-operative day (POD) 4 the patient developed respiratory distress and fever. COVID-19 testing (polymerase chain reaction) was positive. Liver function tests increased approximately 5-fold. Liver biopsy showed moderate acute hepatitis with prominent clusters of apoptotic hepatocytes and associated cellular debris. Lobular lymphohistiocytic inflammation was noted. Typical portal features of mild to moderate acute cellular rejection were also noted."],"journal":"Arch Pathol Lab Med","authors":["Lagana, Stephen M","De Michele, Simona","Lee, Michael J","Emond, Jean C","Griesemer, Adam D","Tulin-Silver, Sheryl A","Verna, Elizabeth C","Martinez, Mercedes","Lefkowitch, Jay H"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302212","week":"202016|Apr 13 - Apr 19","doi":"10.5858/arpa.2020-0186-SA","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664635401384493056,"score":313.38998},{"pmid":32326509,"title":"From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.","text":["From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.","Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT.","Diseases","Nicco, Carole","Paule, Armelle","Konturek, Peter","Edeas, Marvin","32326509"],"abstract":["Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT."],"journal":"Diseases","authors":["Nicco, Carole","Paule, Armelle","Konturek, Peter","Edeas, Marvin"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32326509","week":"202017|Apr 20 - Apr 26","doi":"10.3390/diseases8020009","keywords":["covid-19","fmt","cryoconservation","fecal microbiota transplantation","fecal samples","gut microbiota","stool banks"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996915017678848,"score":305.8605},{"pmid":32243677,"title":"The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs.","text":["The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs.","The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within a few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19, and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource.","Am J Transplant","Angelico, Roberta","Trapani, Silvia","Manzia, Tommaso Maria","Lombardini, Letizia","Tisone, Giuseppe","Cardillo, Massimo","32243677"],"abstract":["The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within a few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19, and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource."],"journal":"Am J Transplant","authors":["Angelico, Roberta","Trapani, Silvia","Manzia, Tommaso Maria","Lombardini, Letizia","Tisone, Giuseppe","Cardillo, Massimo"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243677","week":"202014|Mar 30 - Apr 05","doi":"10.1111/ajt.15904","keywords":["critical care/intensive care management","donors and donation: donor-derived infections","editorial/personal viewpoint","epidemiology","health services and outcomes research","infection and infectious agents - viral","infectious disease","organ procurement and allocation","organ procurement organization","organ transplantation in general"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy","Italy","Italian","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664638249342074880,"score":296.91644}]}